Drug manufacturers Xellia Pharmaceuticals and Chartwell Rx have notified 340B covered entities about possible refunds for overcharges.
Xellia Pharmaceuticals
Drug manufacturers Xellia and Chartwell have notified 340B covered entities about possible refunds for overcharges.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.